Vagnarelli F, Magnani C, Vancini A, Bonacini G, Iori A, Mariani S, Attanasio M, Banchini G
Unità Operativa di Pediatria e Terapia Intensiva Neonatale Arcispedale Santa Maria Nuova, Reggio Emilia.
Acta Biomed Ateneo Parmense. 2000;71 Suppl 1:573-5.
Monthly intramuscular Palivizumab (Synagis, MedImmune, Inc.) is effective in reducing the incidence of RSV-attributable hospitalization by 55% if compared with placebo and seems to be well tolerated.
Our clinical experience in the use of palivizumab in RSV-prophylaxis is presented. During autumn-winter 1999-2000, a total of 8 newborns (gestational age between 28-34 weeks) in our neonatal intensive care unit (NICU) met the AAP recommendations for RSV-immunoprophylaxis. Palivizumab was monthly administered at a dosage of 15 mg/kg i.m. at discharge from the NICU and during the RSV season. Infants were followed up to 40 days from the last injection for adverse reactions and clinical data.
Among eligible newborns, two (28 and 29 weeks respectively) were affected by CLD and required medical therapy at discharge, 4 were born at 29-32 weeks and 2 (both of them born at 34 weeks) had additional risk factors of infection (crowded environment, passive smoking). During RSV season, none of the infants experienced RSV-hospitalization nor lower respiratory tract infection. Mild and transient adverse effects occurred in 2 cases out of 8 (induration in the site of injection and irritability).
In our series of patients, palivizumab resulted safe and effective.
与安慰剂相比，每月肌肉注射帕利珠单抗（商品名：Synagis，MedImmune公司生产）可使呼吸道合胞病毒（RSV）所致住院率降低55%，且耐受性良好。
介绍了我们使用帕利珠单抗预防RSV的临床经验。在1999 - 2000年秋冬季节，我们新生儿重症监护病房（NICU）共有8名新生儿（胎龄28 - 34周）符合美国儿科学会（AAP）关于RSV免疫预防的建议。帕利珠单抗在NICU出院时及RSV流行季节每月肌肉注射一次，剂量为15mg/kg。对婴儿随访至最后一次注射后40天，观察不良反应及临床数据。
在符合条件的新生儿中，2名（分别为28周和29周）患有慢性肺部疾病（CLD），出院时需要药物治疗；4名出生时胎龄为29 - 32周；2名（均为34周出生）有额外的感染风险因素（环境拥挤、被动吸烟）。在RSV流行季节，所有婴儿均未因RSV住院或发生下呼吸道感染。8例中有2例出现轻微短暂的不良反应（注射部位硬结和易激惹）。
在我们的患者系列中，帕利珠单抗安全有效。
